104 results
8-K
EX-99.1
KA
Kineta Inc
17 May 21
Regulation FD Disclosure
5:03pm
results: blinded safety assessment after every cohort for dose escalation or dose adjustment Double Blind Placebo Controlled N=56 N = 8 / cohort (6:2 … / cohort (6:2 ratio YTX-7739 to PBO)* Cohort results: blinded safety assessment after every cohort for dose escalation or dose adjustment Phase 1
8-K
EX-99.1
KA
Kineta Inc
10 Nov 21
Regulation FD Disclosure
7:12am
baseline Exploratory Biomarker: Quantitative EEG Assessment of Brain Activity Shows Baseline Differences Between HV and Parkinson’s Patients … Biomarker: Quantitative EEG Assessment of Brain Activity Shows YTX-7739 Treatment Period Effect in Parkinson’s Patients Alpha-reactivity change
8-K
EX-99.2
KA
Kineta Inc
17 Oct 18
Proteostasis Therapeutics Announces Positive Preliminary Results from
4:30pm
of this presentation. By attending or receiving this presentation you acknowledge you are solely responsible for your own assessment of the market and our market … Evaluate the safety and tolerability of PTI-801 in combination with PTI-808 Measure FEV1 changes as part of the respiratory safety assessment Efficacy
8-K
EX-99.1
KA
Kineta Inc
27 Feb 19
Regulation FD Disclosure
8:00am
. By attending or receiving this presentation you acknowledge you are solely responsible for your own assessment of the market and our market position … of PTI-801 in combination with PTI-808 Measure FEV1 changes as part of the respiratory safety assessment Efficacy Objectives Evaluate the treatment
8-K
EX-99.1
KA
Kineta Inc
28 Nov 18
Regulation FD Disclosure
8:00am
are solely responsible for your own assessment of the market and our market position and that you will conduct your own analysis and are solely … the safety and tolerability of PTI-801 in combination with PTI-808 Measure FEV1 changes as part of the respiratory safety assessment Efficacy Objectives
8-K
EX-99.1
acv5fccaat7b1el ex
7 Jan 19
Departure of Directors or Certain Officers
7:31am
8-K/A
EX-99.7
nz1n7
3 Feb 21
Other Events
4:59pm
8-K
EX-10.1
5v63mnva 4u
4 Mar 22
Entry into a Material Definitive Agreement
4:15pm
S-4
EX-10.18
45sgs05v
23 Sep 20
Registration of securities issued in business combination transactions
4:50pm
10-K
90efh
30 Mar 16
Annual report
12:00am
8-K/A
EX-99.2
2k6u4ybcf qgokdicfgj
3 Feb 21
Other Events
4:59pm
8-K
EX-99.1
p3idtcp1yg mil9y
3 Oct 19
Regulation FD Disclosure
8:01am
8-K
EX-99.1
ggol18zv3v
4 Dec 19
Regulation FD Disclosure
8:10am
8-K
EX-99.1
103h85x6nd8d
13 May 19
Departure of Directors or Certain Officers
8:00am
8-K
EX-99.2
ro13z59
17 Dec 19
Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR
8:30am
8-K
EX-99.2
425xwg
22 Jan 20
Proteostasis Therapeutics Announces Keystone Symposia Presentation of
7:00am
8-K/A
EX-99.1
wmcdpsp ig
13 May 19
Departure of Directors or Certain Officers
5:28pm